



Optibrium and Certara Collaborate on Integration of StarDrop and D360

CAMBRIDGE, UK and PRINCETON, NJ, USA, April 21, 2015 – Optibrium™ and Certara®, developers of software products and services for drug discovery and development, today announced a collaboration to provide their mutual customers with an integrated solution linking Optibrium's StarDrop™ with Certara's D360™ platform. The combination of these two products enables researchers to combine the industry-leading self-service data access and analysis capabilities of D360, with StarDrop's unique, interactive environment that guides compound selection and design decisions in drug discovery, helping project teams to identify high quality compounds more efficiently.

D360 provides scientific data integration, access, analysis, and visualization capabilities for early discovery through to the preclinical and clinical phases of drug development. D360 solves both intra and inter-domain research challenges by integrating data from multiple source systems to provide both standard data views and data mining capabilities. In addition, D360 brings context and understanding to the data, enabling scientists to gain deeper insight and make better scientific decisions. Integration with Optibrium's StarDrop suite enables researchers to seamlessly retrieve their compound data using D360 from within StarDrop's intuitive environment for viewing and interacting with their data in the context of a discovery project. StarDrop provides a highly visual way to interpret data on compounds and their relationships, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery. The combination of the two platforms further extends their capabilities to reduce the time and cost associated with identifying high quality compounds and new optimisation strategies.

Dr Matthew Segall, CEO of Optibrium, commented: "This latest collaboration demonstrates our commitment to delivering a seamless integration between StarDrop and our users' data access infrastructure. We've responded to feedback from global pharma companies that requested integration between these two platforms be made available in the most user-friendly way. We are pleased at the ease with which this integration has been implemented."

"D360 has established a clear position as the leading scientific informatics solution by leveraging Certara's unparalleled domain expertise in biosimulation and scientific informatics", said Dr David Lewis, Certara's Director of Informatics Product Management. "We are excited to add Optibrium to the growing network of D360 partners. Working together we have enabled our clients to further optimise their work by leveraging D360's open architecture to seamlessly connect StarDrop with the data mining and analytics capabilities provided by D360."

The results of this collaboration are available to existing clients using D360 and StarDrop 6.0.

For further information on Optibrium and StarDrop, please visit www.optibrium.com/stardrop/, contact info@optibrium.com or call +44 1223 815900.

For further information on D360 or Certara's other products and services, please visit www.certara.com, contact david.louis@certara.com or call +1 (314) 951-3353.

ENDS

Media contact

Sarah Jeffery

Zyme Communications

E-mail: sarah.jeffery@zymecommunications.com

Phone: +44 (0) 7771 730919

Optibrium

Nick Foster

Director, Business Development

E-mail: nick.foster@optibrium.com

Phone: +44 (0)1223 815900

Certara USA Inc.

Ellen Leinfuss, 609-216-9586

Chief Marketing Officer

E-mail: ellen.leinfuss@certara.com

Phone:

About Optibrium Ltd.

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium's portfolio of products includes:

- StarDrop™, which brings confidence to the selection and design of high quality candidate compounds. StarDrop creates an intuitive, highly visual and flexible environment to facilitate and speed up lead identification and optimisation, quickly targeting effective candidate compounds with a high probability of success downstream.
- Sentira™, an easy-to-use, dynamic data visualisation platform that helps to quickly spot patterns in compound data, analyse structure-activity relationships and elegantly present and report results.
- Asteris™, an iPad app that enables researchers to explore new compound ideas when and where they want, by combining highly intuitive chemistry drawing tools with StarDrop's visually informative predictive modelling.

Founded in 2009, Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

Visit the online community at <http://www.optibrium.com/community/> for further discussions on improving the productivity of drug discovery.

About Certara

Certara is the global biosimulation and informatics technology-enabled drug development and drug safety consulting company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara's solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.